Pub Date : 2017-01-01DOI: 10.17925/ENR.2017.12.02.87
K. Cook, R. Suresh, K. Lou, J. Kesslak, D. Fredericks
P arkinson’s disease psychosis (PDP) is a clinical condition that affects patients diagnosed with Parkinson’s disease (PD) and has a spectrum of neuropsychiatric symptoms distinct from the hallmark motor symptoms. Although prior studies have reported on the prevalence of PDP in select European nations, variations in study design complicate study-to-study comparisons. In this study, we surveyed 1,667 medical practitioners across France, Germany, Italy, Spain, and the UK (collectively, the EU-5) to estimate the prevalence of PDP or symptoms of psychosis among patients with PD. Analysis of the survey data suggest approximately 29% of the general PD population in the EU-5 exhibit signs of PDP. Among the PD population, country-specific rates of PDP are estimated at 30% in France, 27% in Germany, 34% in Italy, 30% in Spain and 21% in the UK. These rates appear in line with those reported in prior country-specific studies. Results from the subset of 437 neurologists who proceeded to take the full survey suggest the symptoms of PDP are disruptive to patients or their respective caregivers in approximately 53% of cases. These results provide a resource that enables cross-country comparison of PDP rates across these major European nations.
{"title":"Parkinson’s Disease Psychosis – Prevalence Patterns Across the EU-5","authors":"K. Cook, R. Suresh, K. Lou, J. Kesslak, D. Fredericks","doi":"10.17925/ENR.2017.12.02.87","DOIUrl":"https://doi.org/10.17925/ENR.2017.12.02.87","url":null,"abstract":"P arkinson’s disease psychosis (PDP) is a clinical condition that affects patients diagnosed with Parkinson’s disease (PD) and has a spectrum of neuropsychiatric symptoms distinct from the hallmark motor symptoms. Although prior studies have reported on the prevalence of PDP in select European nations, variations in study design complicate study-to-study comparisons. In this study, we surveyed 1,667 medical practitioners across France, Germany, Italy, Spain, and the UK (collectively, the EU-5) to estimate the prevalence of PDP or symptoms of psychosis among patients with PD. Analysis of the survey data suggest approximately 29% of the general PD population in the EU-5 exhibit signs of PDP. Among the PD population, country-specific rates of PDP are estimated at 30% in France, 27% in Germany, 34% in Italy, 30% in Spain and 21% in the UK. These rates appear in line with those reported in prior country-specific studies. Results from the subset of 437 neurologists who proceeded to take the full survey suggest the symptoms of PDP are disruptive to patients or their respective caregivers in approximately 53% of cases. These results provide a resource that enables cross-country comparison of PDP rates across these major European nations.","PeriodicalId":12047,"journal":{"name":"European neurological review","volume":"12 1","pages":"87"},"PeriodicalIF":0.0,"publicationDate":"2017-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"67592436","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2017-01-01DOI: 10.17925/ENR.2017.12.02.84
J. Reuck
{"title":"Cerebrovascular Lesions in Pick Complex Diseases – A Neuropathological Study with a 7.0-Tesla Magnetic Resonance Imaging Study","authors":"J. Reuck","doi":"10.17925/ENR.2017.12.02.84","DOIUrl":"https://doi.org/10.17925/ENR.2017.12.02.84","url":null,"abstract":"","PeriodicalId":12047,"journal":{"name":"European neurological review","volume":"12 1","pages":"84"},"PeriodicalIF":0.0,"publicationDate":"2017-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"67592375","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2017-01-01DOI: 10.17925/USN.2017.13.01.26
Jeffrey A. Allen, D. Gelinas, R. Lewis, R. Nowak, G. Wolfe
Disclosure: Jeffrey A Allen is a consultant for, and has received clinical trial support, from: Axelacare, CSL Behring, and Grifols. Deborah F Gelinas is an employee of Grifols, and is on the Avanir Speaker Bureau for Nuedexta. Richard A Lewis is a consultant for Axelacare, CSL Behring, Biotest Pharma, Kedrion, and Pharnext. Richard J Nowak is a speaker and advisor/consultant for Grifols. Gil I Wolfe participated in Shire and Grifols advisory boards and received research support from CSL Behring.
披露:Jeffrey A Allen是Axelacare、CSL Behring和Grifols的临床试验顾问，并获得了这些公司的支持。黛博拉·F·吉利纳斯是Grifols的一名员工，也是Nuedexta Avanir Speaker Bureau的一员。Richard A . Lewis是Axelacare、CSL Behring、Biotest Pharma、Kedrion和Pharnext的顾问。理查德·J·诺瓦克(Richard J Nowak)是Grifols的演讲者和顾问。Gil I Wolfe参加了Shire和Grifols顾问委员会，并获得了CSL Behring的研究支持。
{"title":"Optimizing the use of outcome measures in chronic inflammatory demyelinating polyneuropathy","authors":"Jeffrey A. Allen, D. Gelinas, R. Lewis, R. Nowak, G. Wolfe","doi":"10.17925/USN.2017.13.01.26","DOIUrl":"https://doi.org/10.17925/USN.2017.13.01.26","url":null,"abstract":"Disclosure: Jeffrey A Allen is a consultant for, and has received clinical trial support, from: Axelacare, CSL Behring, and Grifols. Deborah F Gelinas is an employee of Grifols, and is on the Avanir Speaker Bureau for Nuedexta. Richard A Lewis is a consultant for Axelacare, CSL Behring, Biotest Pharma, Kedrion, and Pharnext. Richard J Nowak is a speaker and advisor/consultant for Grifols. Gil I Wolfe participated in Shire and Grifols advisory boards and received research support from CSL Behring.","PeriodicalId":12047,"journal":{"name":"European neurological review","volume":"13 1","pages":"26-33"},"PeriodicalIF":0.0,"publicationDate":"2017-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"67611694","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2016-03-01DOI: 10.17925/USN.2016.12.01.22
Krishna Pokala, D. Girard, S. Beydoun
{"title":"Different Presentations of Myelopathy—A Case Series","authors":"Krishna Pokala, D. Girard, S. Beydoun","doi":"10.17925/USN.2016.12.01.22","DOIUrl":"https://doi.org/10.17925/USN.2016.12.01.22","url":null,"abstract":"","PeriodicalId":12047,"journal":{"name":"European neurological review","volume":"12 1","pages":"22-26"},"PeriodicalIF":0.0,"publicationDate":"2016-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"67611842","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2016-01-01DOI: 10.17925/ENR.2016.11.02.106
F. Puledda, P. Goadsby
N euromodulation represents an exciting new approach that is being increasingly used as both acute and preventative treatment for migraine, providing a valid alternative option for patients for whom traditional drugs have failed, or for those who do not tolerate their side effects. This brief review aims at describing noninvasive neuromodulation techniques, which are currently the most used in clinical practice, specifically focusing on transcranial magnetic stimulation, vagus nerve stimulation and supraorbital nerve stimulation.
{"title":"The Role of Noninvasive Neuromodulation in Migraine Management","authors":"F. Puledda, P. Goadsby","doi":"10.17925/ENR.2016.11.02.106","DOIUrl":"https://doi.org/10.17925/ENR.2016.11.02.106","url":null,"abstract":"N euromodulation represents an exciting new approach that is being increasingly used as both acute and preventative treatment for migraine, providing a valid alternative option for patients for whom traditional drugs have failed, or for those who do not tolerate their side effects. This brief review aims at describing noninvasive neuromodulation techniques, which are currently the most used in clinical practice, specifically focusing on transcranial magnetic stimulation, vagus nerve stimulation and supraorbital nerve stimulation.","PeriodicalId":12047,"journal":{"name":"European neurological review","volume":"11 1","pages":"106"},"PeriodicalIF":0.0,"publicationDate":"2016-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"67592023","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2016-01-01DOI: 10.17925/ENR.2016.11.02.87
D. Bowers, K. Fheodoroff, P. Khan, J. Harriss, K. Dashtipour, L. Bahroo, Michael Y. Lee, D. Zakharov, J. Balcaitiene, V. Evidente
{"title":"Spastic Paresis and Rehabilitation – The Patient Journey","authors":"D. Bowers, K. Fheodoroff, P. Khan, J. Harriss, K. Dashtipour, L. Bahroo, Michael Y. Lee, D. Zakharov, J. Balcaitiene, V. Evidente","doi":"10.17925/ENR.2016.11.02.87","DOIUrl":"https://doi.org/10.17925/ENR.2016.11.02.87","url":null,"abstract":"","PeriodicalId":12047,"journal":{"name":"European neurological review","volume":"11 1","pages":"87"},"PeriodicalIF":0.0,"publicationDate":"2016-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"67592127","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2016-01-01DOI: 10.17925/ENR.2016.11.01.1a
P. Kelly, C. Molina, C. Ruff, R. Veltkamp
The rising incidence of atrial fibrillation (AF) is increasingly resulting in a substantial worldwide increase in AF-related stroke, particularly in elderly patients and this is creating an increasingly serious healthcare burden. Guidelines recommend the use of AF-related stroke prophylaxis but adherence to these remains poor. Studies conducted in the 1990s showed that warfarin reduced the risk of AF-related stroke by an overall 64% compared with placebo. Subsequently, prophylactic treatment was further improved with the development of non-vitamin K antagonist oral anticoagulants (NOACs). More recently, a meta-analysis of four large clinical trials on NOACs (dabigatran, rivaroxaban, apixaban, and edoxaban) showed there was a relative risk reduction of 0.81 (p<0.0001) favouring NOAC treatment over warfarin for stroke or systemic embolic events in patients with AF. The largest trial of NOACs in AF-related stroke, to date, was the ENGAGE AF-TIMI 48 study (n=21,105) which showed that edoxaban was non-inferior to warfarin for ischaemic stroke reduction but significantly reduced bleeding and cardiovascular mortality. A recent subgroup analysis of this study showed that with edoxaban the incidences of intracranial haemorrhage (ICH) subtypes (all ICH, fatal ICH, fatal, subdural and epidural bleed) were significantly lower with 60 mg of edoxaban (p=0.013–<0.001). Edoxaban was also shown to be an effective option in patients with prior stroke. In addition, edoxaban was shown to reduce deaths due to fatal bleeds compared with warfarin. The results of current studies, especially the ENGAGE AF-TIMI 48 subgroup analysis therefore, show that the benefits of anticoagulation therapy in patients with AF substantially outweigh the risks.
{"title":"Improving Patient Outcomes in Preventing Atrial Fibrillation-related Stroke with Non-Vitamin K Antagonist Oral Anticoagulants","authors":"P. Kelly, C. Molina, C. Ruff, R. Veltkamp","doi":"10.17925/ENR.2016.11.01.1a","DOIUrl":"https://doi.org/10.17925/ENR.2016.11.01.1a","url":null,"abstract":"The rising incidence of atrial fibrillation (AF) is increasingly resulting in a substantial worldwide increase in AF-related stroke, particularly in elderly patients and this is creating an increasingly serious healthcare burden. Guidelines recommend the use of AF-related stroke prophylaxis but adherence to these remains poor. Studies conducted in the 1990s showed that warfarin reduced the risk of AF-related stroke by an overall 64% compared with placebo. Subsequently, prophylactic treatment was further improved with the development of non-vitamin K antagonist oral anticoagulants (NOACs). More recently, a meta-analysis of four large clinical trials on NOACs (dabigatran, rivaroxaban, apixaban, and edoxaban) showed there was a relative risk reduction of 0.81 (p<0.0001) favouring NOAC treatment over warfarin for stroke or systemic embolic events in patients with AF. The largest trial of NOACs in AF-related stroke, to date, was the ENGAGE AF-TIMI 48 study (n=21,105) which showed that edoxaban was non-inferior to warfarin for ischaemic stroke reduction but significantly reduced bleeding and cardiovascular mortality. A recent subgroup analysis of this study showed that with edoxaban the incidences of intracranial haemorrhage (ICH) subtypes (all ICH, fatal ICH, fatal, subdural and epidural bleed) were significantly lower with 60 mg of edoxaban (p=0.013–<0.001). Edoxaban was also shown to be an effective option in patients with prior stroke. In addition, edoxaban was shown to reduce deaths due to fatal bleeds compared with warfarin. The results of current studies, especially the ENGAGE AF-TIMI 48 subgroup analysis therefore, show that the benefits of anticoagulation therapy in patients with AF substantially outweigh the risks.","PeriodicalId":12047,"journal":{"name":"European neurological review","volume":"700 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2016-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"67591789","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2016-01-01DOI: 10.17925/ENR.2016.11.02.96
G. Giovannoni
{"title":"Efficacy and Safety of Existing and Emerging Monoclonal Antibody Therapies for Multiple Sclerosis","authors":"G. Giovannoni","doi":"10.17925/ENR.2016.11.02.96","DOIUrl":"https://doi.org/10.17925/ENR.2016.11.02.96","url":null,"abstract":"","PeriodicalId":12047,"journal":{"name":"European neurological review","volume":"11 1","pages":"96"},"PeriodicalIF":0.0,"publicationDate":"2016-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"67592176","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2016-01-01DOI: 10.17925/ENR.2016.11.02.109
L. Kumar, E. Athanasakos, A. Emmanuel
N eurogenic bowel dysfunction is a severely troubling entity for patients with neurological disease or injury. The complex symptom cluster presents a challenge, not only for the patients but also for the treating clinician. Without intervention, patients are bound to have a reduced quality of life, and experience social impacts and secondary complications that come along with it. A careful initial assessment provides an idea of symptom severity and is crucial for successful rehabilitation. The mainstay of treatment remains a conservative approach of managing faecal incontinence or optimising the mechanics of defecation to improve patient’s quality of life. This article attempts to provide a comprehensive review of existing literature on pathophysiology, assessment and management of neurogenic bowel dysfunction.
{"title":"Evaluation and Treatment of Neurogenic Bowel Dysfunction – A Review","authors":"L. Kumar, E. Athanasakos, A. Emmanuel","doi":"10.17925/ENR.2016.11.02.109","DOIUrl":"https://doi.org/10.17925/ENR.2016.11.02.109","url":null,"abstract":"N eurogenic bowel dysfunction is a severely troubling entity for patients with neurological disease or injury. The complex symptom cluster presents a challenge, not only for the patients but also for the treating clinician. Without intervention, patients are bound to have a reduced quality of life, and experience social impacts and secondary complications that come along with it. A careful initial assessment provides an idea of symptom severity and is crucial for successful rehabilitation. The mainstay of treatment remains a conservative approach of managing faecal incontinence or optimising the mechanics of defecation to improve patient’s quality of life. This article attempts to provide a comprehensive review of existing literature on pathophysiology, assessment and management of neurogenic bowel dysfunction.","PeriodicalId":12047,"journal":{"name":"European neurological review","volume":"11 1","pages":"109"},"PeriodicalIF":0.0,"publicationDate":"2016-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"67592065","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
京公网安备 11010802042870号
京ICP备2023020795号-1
扫码关注我们
求助内容：
应助结果提醒方式：